WO2000028011A3 - Fk506-based regulation of biological events - Google Patents

Fk506-based regulation of biological events Download PDF

Info

Publication number
WO2000028011A3
WO2000028011A3 PCT/US1999/025766 US9925766W WO0028011A3 WO 2000028011 A3 WO2000028011 A3 WO 2000028011A3 US 9925766 W US9925766 W US 9925766W WO 0028011 A3 WO0028011 A3 WO 0028011A3
Authority
WO
WIPO (PCT)
Prior art keywords
cab
ligand
domain
protein
cyclophilin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1999/025766
Other languages
French (fr)
Other versions
WO2000028011A2 (en
Inventor
Paul A Clemons
Brian G Gladstone
Abhinav Seth
Stuart L Schreiber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harvard University
Original Assignee
Harvard University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard University filed Critical Harvard University
Priority to CA002346962A priority Critical patent/CA2346962A1/en
Priority to JP2000581178A priority patent/JP2002529081A/en
Priority to EP99958742A priority patent/EP1127140A2/en
Priority to AU16039/00A priority patent/AU1603900A/en
Publication of WO2000028011A2 publication Critical patent/WO2000028011A2/en
Publication of WO2000028011A3 publication Critical patent/WO2000028011A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/71—Fusion polypeptide containing domain for protein-protein interaction containing domain for transcriptional activaation, e.g. VP16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/71—Fusion polypeptide containing domain for protein-protein interaction containing domain for transcriptional activaation, e.g. VP16
    • C07K2319/715—Fusion polypeptide containing domain for protein-protein interaction containing domain for transcriptional activaation, e.g. VP16 containing a domain for ligand dependent transcriptional activation, e.g. containing a steroid receptor domain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Environmental Sciences (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

This invention provides methods and materials for making and using genetically engineered cells which are responsive to the presence of an FKBP/CAB ligand or a cyclophilin/CAB ligand. The invention relies upon the introduction into cells of recombinant DNAs encoding fusion proteins which are capable of forming a complex with each other in the presence of ligand. One of the fusion proteins contains a calcineurin A/calcineurin B domain (CAB) and at least one heterologous protein domain. The second fusion protein contains a domain derived from an FKBP protein which is capable of binding to an FKBP/CAB ligand and forming a complex with a CAB-containing protein. The second fusion protein may alternatively contain a cyclophilin domain which is capable of binding cyclosporin or other cyclophilin/CAB ligand and forming a complex with a CAB-containing protein. The second fusion protein also contains at least one heterologous domain.
PCT/US1999/025766 1998-11-06 1999-11-05 Fk506-based regulation of biological events Ceased WO2000028011A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002346962A CA2346962A1 (en) 1998-11-06 1999-11-05 Fk506-based regulation of biological events
JP2000581178A JP2002529081A (en) 1998-11-06 1999-11-05 FK506-based modulation of biological events
EP99958742A EP1127140A2 (en) 1998-11-06 1999-11-05 Fk506-based regulation of biological events
AU16039/00A AU1603900A (en) 1998-11-06 1999-11-05 Fk506-based regulation of biological events

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10747398P 1998-11-06 1998-11-06
US60/107,473 1998-11-06

Publications (2)

Publication Number Publication Date
WO2000028011A2 WO2000028011A2 (en) 2000-05-18
WO2000028011A3 true WO2000028011A3 (en) 2000-11-23

Family

ID=22316797

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/025766 Ceased WO2000028011A2 (en) 1998-11-06 1999-11-05 Fk506-based regulation of biological events

Country Status (5)

Country Link
EP (1) EP1127140A2 (en)
JP (1) JP2002529081A (en)
AU (1) AU1603900A (en)
CA (1) CA2346962A1 (en)
WO (1) WO2000028011A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03011455A (en) 2001-06-22 2004-04-05 Hoffmann La Roche A soluble complex comprising a retroviral surface glycoprotein.
US7094757B2 (en) 2001-06-22 2006-08-22 Roche Diagnostics Corporation Complexes comprising a prion protein and a peptidyl prolyl isomerase chaperone, and method for producing and using them
ATE491947T1 (en) 2006-01-27 2011-01-15 Univ Wuerzburg J Maximilians PEPTIDE FOR INHIBITING CALCINEURIN
CN105785027A (en) * 2015-12-30 2016-07-20 海口奇力制药股份有限公司 Combined reagent and application thereof, kit containing combined reagent and detecting method
MX2021008824A (en) * 2019-01-23 2021-10-13 Univ Johns Hopkins Non-immunosuppressive fk506 analogs and use thereof.

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994018317A1 (en) * 1993-02-12 1994-08-18 The Board Of Trustees Of The Leland Stanford Junior University Regulated transcription of targeted genes and other biological events
EP0618227A1 (en) * 1993-04-01 1994-10-05 Amgen Inc. Biologically active polypeptide fusion dimers
WO1996012806A1 (en) * 1994-10-24 1996-05-02 The Board Of Trustees Of The Leland Stanford Junior University Calcineurin interacting protein compositions and methods
WO1996016172A2 (en) * 1994-11-23 1996-05-30 Icos Corporation Modulators of anchoring protein function
WO1997006246A2 (en) * 1995-08-09 1997-02-20 Vertex Pharmaceuticals Incorporated Molecules comprising a calcineurin-like binding pocket and encoded data storage medium capable of graphically displaying them

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994018317A1 (en) * 1993-02-12 1994-08-18 The Board Of Trustees Of The Leland Stanford Junior University Regulated transcription of targeted genes and other biological events
EP0618227A1 (en) * 1993-04-01 1994-10-05 Amgen Inc. Biologically active polypeptide fusion dimers
WO1996012806A1 (en) * 1994-10-24 1996-05-02 The Board Of Trustees Of The Leland Stanford Junior University Calcineurin interacting protein compositions and methods
WO1996016172A2 (en) * 1994-11-23 1996-05-30 Icos Corporation Modulators of anchoring protein function
WO1997006246A2 (en) * 1995-08-09 1997-02-20 Vertex Pharmaceuticals Incorporated Molecules comprising a calcineurin-like binding pocket and encoded data storage medium capable of graphically displaying them

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
M.T. KENNEDY ET AL.,: "Contributions of Myristoylation to Calcineurin Structure/Function", J. BIOL. CHEM., vol. 271, no. 43, 25 October 1996 (1996-10-25), US, pages 26517 - 26521, XP002140377 *
Q. WEI AND E.Y. LEE: "Expression and reconstitution of calcineurin A and B subunits", BIOCHEM. MOL. BIOL. INT., vol. 41, no. 1, January 1997 (1997-01-01), pages 169 - 177, XP000915910 *

Also Published As

Publication number Publication date
AU1603900A (en) 2000-05-29
WO2000028011A2 (en) 2000-05-18
JP2002529081A (en) 2002-09-10
CA2346962A1 (en) 2000-05-18
EP1127140A2 (en) 2001-08-29

Similar Documents

Publication Publication Date Title
Maggi The mammalian tachykinin receptors
WO2000060066A8 (en) Protein-protein from s. cerevisiae and methods of using same
EP1097994A3 (en) Human bad polypeptides, encoding nucleic acids and methods of use
WO1998018826A3 (en) Anti-CCR5 antibodies and methods of use therefor
EP0960939A3 (en) Dual-tagged proteins and their uses
WO1996016172A3 (en) Modulators of anchoring protein function
AU6020598A (en) Dna sequences, vectors, and fusion polypeptides for secretion of polypeptides infilamentous fungi
WO2001087919A3 (en) Methods of detecting interactions between proteins, peptides or libraries thereof using fusion proteins
WO2001021796A3 (en) Gl50 molecules and uses therefor
WO1999057149A3 (en) Compounds and methods for modulating nonclassical cadherin-mediated functions
WO1999007728A3 (en) Linear peptides derived from antibiotic peptides, preparation and use for vectoring active substances
AU2001286730A1 (en) An iap binding peptide or polypeptide and methods of using the same
WO1997026321A3 (en) Recombinant expression of proteins from secretory cell lines
NZ333329A (en) Polypeptides capable of forming antigen binding structures with specificity for rhesus d antigens
WO1999009186A3 (en) Polypeptide nucleic sequences exported from mycobacteria, vectors comprising same and uses for diagnosing and preventing tuberculosis
WO1999045098A3 (en) Delivery or proteins into eukaryotic cells with recombinant yersinia
CA2166850A1 (en) Vectors and Use Thereof for Capturing Target Genes
WO2000028011A3 (en) Fk506-based regulation of biological events
CA2173102A1 (en) Dna sequence coding for a bmp receptor
WO2001044809A3 (en) Evaluation of biological agents in living target cells
EP0992584A3 (en) Purified mammalian FLT3 ligands and agonists and antagonists thereof
WO2002048403A3 (en) Multiplexed protein expression and activity assay
WO1997045746A3 (en) Prion protein binding proteins and uses thereof
AU3623197A (en) Peptide reagent for the detection of human cytomegalovirus (cmv)
WO1998037180A3 (en) Hcv fusion protease and polynucleotide encoding same

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref country code: AU

Ref document number: 2000 16039

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

ENP Entry into the national phase

Ref document number: 2346962

Country of ref document: CA

Ref country code: CA

Ref document number: 2346962

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 581178

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 16039/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1999958742

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999958742

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09831096

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 1999958742

Country of ref document: EP